Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5462 + dapagliflozin in heart failure with renal impairment
NCT06639087Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing AZD5462 + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Change in sodium excretion at 1 day. Started Sep 2024; status: terminated.
02
Drugs
AZD5462
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06639087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639087.